

DOI: 10.4103/0971-5916.272085



Authors' response

We thank the author¹ for her interest in our study².

- (i) The authors have mentioned about the definition of a pandrug-resistant (PDR) isolate as described by Ghafur *et al*³. This implies that the criteria have been followed to brand the organism as a PDR.
- (ii) It is agreed that the CLSI/EUCAST-approved micro broth dilution remains a challenge till date in routine microbiology laboratories. Hence, this is not being used in our laboratory which is a routine laboratory only. Instead, the available and accessible methods are used. Hence, susceptibility to colistin has been determined by E-strip as well as correlating it with VITEK-2 minimum inhibitory concentration reports. We are aware that both these methods can have major errors. Therefore, it has been stated that colistin susceptibility has to be interpreted with caution and treatment should be done only after judicious clinical assessment. The isolates were judged as pathogen or colonizer by two independent assessors before being actually treated.

**Sharmili Sinha^{1*}, Suneeta Sahu², Jyotirmaya Pati¹,
Banambar Ray¹ & Saroj Kumar Pattnaik¹**

Departments of ¹Critical Care Medicine
& ²Microbiology, Apollo Hospitals,
Bhubaneswar 751 005, Odisha, India

**For correspondence:*
sharmili.sinha@yahoo.co.in

Received August 28, 2019

References

1. Behara B. Challenges & issues of colistin susceptibility testing in diagnostic microbiology laboratories. *Indian J Med Res* 2019; 150 : 417-8.
2. Sinha S, Sahu S, Pati J, Ray B, Pattnaik SK. Retrospective analysis of colistin-resistant bacteria in a tertiary care centre in India. *Indian J Med Res* 2019; 149 : 418-22.
3. Ghafur A, Vidyalakshmi PR, Murali A, Priyadarshini K, Thirunarayan MA. Emergence of pan-drug resistance amongst Gram-negative bacteria. The first case series from India. *J Microbial Infect Disease* 2014; 4 : 86-91.